

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/51680528>

# A Small Molecule Mimicking a Phosphatidylinositol (4,5)-Bisphosphate Binding Pleckstrin Homology Domain

ARTICLE in ACS CHEMICAL BIOLOGY · SEPTEMBER 2011

Impact Factor: 5.33 · DOI: 10.1021/cb2003187 · Source: PubMed

---

CITATIONS

13

READS

60

## 7 AUTHORS, INCLUDING:



[Savvas Georgiades](#)

University of Cyprus

17 PUBLICATIONS 326 CITATIONS

[SEE PROFILE](#)



[Gillian F \(Whyte\) Lovell](#)

Imperial College London

3 PUBLICATIONS 26 CITATIONS

[SEE PROFILE](#)



[Ramon Vilar](#)

Imperial College London

137 PUBLICATIONS 4,872 CITATIONS

[SEE PROFILE](#)



[Rüdiger Woscholski](#)

Imperial College London

73 PUBLICATIONS 3,242 CITATIONS

[SEE PROFILE](#)

# A Small Molecule Mimicking a Phosphatidylinositol (4,5)-Bisphosphate Binding Pleckstrin Homology Domain

Lok Hang Mak,<sup>†,‡</sup> Savvas N. Georgiades,<sup>†</sup> Evelyn Rosivatz,<sup>‡</sup> Gillian F. Whyte,<sup>†,§</sup> Marianna Mirabelli,<sup>†</sup> Ramon Vilar,<sup>†,§\*</sup> and Rudiger Woscholski<sup>†,§,\*</sup>

<sup>†</sup>Department of Chemistry, <sup>‡</sup>Division of Cell and Molecular Biology, and <sup>§</sup>Institute of Chemical Biology, Imperial College London, Exhibition Road, London SW7 2AZ, U.K.

 Supporting Information

**ABSTRACT:** Inositol phospholipids have emerged as important key players in a wide variety of cellular functions. Among the seven existing inositol phospholipids, phosphatidylinositol (4,5)-bisphosphate ( $\text{PI}(4,5)\text{P}_2$ ) has attracted much attention in recent years due to its important role in numerous cellular signaling events and regulations, which in turn impact several human diseases. This particular lipid is recognized in the cell by specific lipid binding domains, such as the Pleckstrin-homology (PH) domain, which is also employed as a tool to monitor this important lipid. Here, we describe the synthesis and biological characterization of a small molecule that mimics the PH domain as judged by its ability to bind specifically to only  $\text{PI}(4,5)\text{P}_2$  and effectively compete with the PH domain *in vitro* and in a cellular environment. The binding constant of this small molecule PH domain mimetic (PHDM) was determined to be  $17.6 \pm 10.1 \mu\text{M}$ , similar in potency to the PH domain. Using NIH 3T3 mouse fibroblast cells we demonstrated that this compound is cell-permeable and able to modulate  $\text{PI}(4,5)\text{P}_2$ -dependent effects in a cellular environment such as the endocytosis of the transferrin receptor, loss of mitochondria, as well as stress fiber formation. This highly  $\text{PI}(4,5)\text{P}_2$ -specific chemical mimetic of a PH domain not only is a powerful research tool but might also be a lead compound in future drug developments targeting  $\text{PI}(4,5)\text{P}_2$ -dependent diseases such as Lowe syndrome.

Phosphatidylinositol 4,5-bisphosphate ( $\text{PI}(4,5)\text{P}_2$ ) is an important inositol phospholipid, since it is the precursor for several second messengers, such as phosphatidylinositol 3,4,5-trisphosphate ( $\text{PIP}_3$ ),<sup>1</sup> diacylglycerol, and 1,4,5-trisphosphate ( $\text{IP}_3$ ).<sup>2</sup> In addition,  $\text{PI}(4,5)\text{P}_2$  interacts with a variety of proteins such as profilin, gelsolin, and  $\alpha$ -actinin, which regulate the polymerization and depolymerization of actin in the cytoskeleton.<sup>3,4</sup> Recently, it has been demonstrated that  $\text{PI}(4,5)\text{P}_2$  plays an important role in the processes of exocytosis and endocytosis, as well as the regulation of a variety of ion channels,<sup>5</sup> suggesting that  $\text{PI}(4,5)\text{P}_2$  could be a key regulator of many cellular processes and diseases.<sup>6</sup> Lowe syndrome, for example, is caused by the mutation of the inositol-5-phosphatase OCRL, resulting in elevated  $\text{PI}(4,5)\text{P}_2$  levels.<sup>6</sup>

Cellular levels of this lipid are maintained mainly by a balance between the phosphatidylinositol-monophosphate kinases (synthesis) and the counteracting phosphatidylinositol phosphatases (breakdown).<sup>7,8</sup> Changes of  $\text{PI}(4,5)\text{P}_2$  levels are detected by lipid-binding proteins *via* lipid recognition domains such as the pleckstrin homology domain (PH domain), which possesses submicromolar affinity and specificity for  $\text{PI}(4,5)\text{P}_2$ .<sup>9</sup> For example, the PH domain of phospholipase C- $\delta$ 1 selectively binds  $\text{PI}(4,5)\text{P}_2$  and its head group  $\text{IP}_3$  and thus has been applied as a tool to detect and image  $\text{PI}(4,5)\text{P}_2$  levels.<sup>10</sup> Furthermore, this PH domain has also been employed as a  $\text{PI}(4,5)\text{P}_2$  sequestering tool causing a loss of available  $\text{PI}(4,5)\text{P}_2$  levels. As demonstrated by Raucher *et al.*,<sup>4</sup> overexpression of this PH domain resulted in the loss of actin stress fibers (cytoskeleton), an effect that could also be observed by overexpression of a  $\text{PI}(4,5)\text{P}_2$ -specific phosphatase. Thus, sequestering (PH domain binding) and removal (phosphatase) of cellular  $\text{PI}(4,5)\text{P}_2$  affects cellular function in a similar fashion.

Chemical alternatives to alter cellular  $\text{PI}(4,5)\text{P}_2$  concentrations do not really exist. Neomycin as well as polylysine have been proposed as tools to sequester cellular  $\text{PI}(4,5)\text{P}_2$ , but their use is restricted due to the lack of sufficient potency and selectivity,<sup>11–13</sup> leaving a real void of chemical receptors that would be able to recognize a specific inositol phosphate in a cellular environment. We therefore set out to design a chemical receptor that would be able to do this. In this paper we present the development of such a receptor and detailed studies of its ability to bind  $\text{PI}(4,5)\text{P}_2$  *in vitro* and *in vivo*. This is the first report on a small molecule able to recognize  $\text{PI}(4,5)\text{P}_2$  displaying high affinity and specificity, effectively mimicking a PH domain.


## RESULTS AND DISCUSSION

**Design and Development of a Chemical Receptor for  $\text{PI}(4,5)\text{P}_2$ .** In order to design a specific chemical receptor for  $\text{PI}(4,5)\text{P}_2$  that is capable of mimicking the efficacy of the equivalent biological tools (*e.g.*, PH domain), unique recognition motifs in the targeted molecule have to be utilized. The head group of  $\text{PI}(4,5)\text{P}_2$  contains phosphate and hydroxyl functionalities (see Figure 1a) that can be exploited for this purpose. For example, it is well established that ureas can form complementary hydrogen-bonding interactions with phosphates,<sup>14–17</sup> while boronic acids have been successfully used for the molecular recognition of diols *via* the reversible formation of B–O covalent bonds.<sup>18,19</sup> Thus, we designed a chemical receptor (PHDM) that

**Received:** May 13, 2011

**Accepted:** September 29, 2011

**Published:** September 29, 2011



**Figure 1.** (a) Chemical structure of D-myoinositol (1,4,5)P<sub>3</sub>. (b) Chemical structure of receptor (PHDM) with diol and phosphate-binding groups; a large and relatively rigid spacer allows for two separate PI(4,5)P<sub>2</sub> binding pockets to be present in the same molecule. (c) Space-fill computer model of the receptor under study (PHDM) binding two different PI(4,5)P<sub>2</sub> molecules (the receptor is shown in black and the PI(4,5)P<sub>2</sub> molecules in white). Hydrogens have been omitted for clarity; the aliphatic chain attached to PI(4,5)P<sub>2</sub> was substituted for shorter propyl groups to simplify the calculations. Optimization was carried out by molecular mechanics first, MM2 force field, followed by DFT calculations at the B3LYP/6-31G level using Gaussian.

utilizes ureas and boronic acids as recognition motifs (see Figure 1b). In this receptor, a large central spacer was employed with the aim of generating two recognition pockets (each containing a urea, secondary amine, and a phenyl boronic acid group), which allows binding to two target molecules (see Figure 1c). This approach of a tandem receptor has been successfully used to increase specificity and affinity of biological lipid recognition domains,<sup>20</sup> a benefit desired for our chemical receptor designed here.

The PI(4,5)P<sub>2</sub> receptor PHDM was synthesized *via* the three-step process shown in Scheme 1. First, monoprotected amine **1** was reacted with 2-formylphenylboronic acid followed by reduction (with NaBH<sub>4</sub>) of the resulting imine to yield compound **2**. This was followed by deprotection of the benzylamine to generate compound **3**, which was reacted with 4,4'-methylenebis(phenyl isocyanate) to yield the bis-urea, bis-boronic acid target compound PHDM. The purity and integrity of PHDM was confirmed by <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy, IR spectroscopy, mass spectrometry, HPLC separation (which showed only one trace), and elemental analyses (see Methods section).




**PHDM Binds PI(4,5)P<sub>2</sub>.** To demonstrate the ability of the PHDM to bind PI(4,5)P<sub>2</sub>, we developed an enzyme-linked immunosorbent assay (ELISA) where we employed the PH domain of phospholipase C-δ1 (PLC-δ1) to detect the available PI(4,5)P<sub>2</sub> after exposure to increasing concentrations of PHDM (see Supplementary Figure 1). Since this assay provides a linear detection range in the presence of 80–500 nM PH domain (Figure 2b), the competition ELISA was performed with varying PHDM concentrations in the presence of 125 nM PH domain. As shown in Figure 2b, PHDM affects the binding of the PLC-δ1-PH domain to PI(4,5)P<sub>2</sub> already at very low concentrations ( $\sim 3 \mu\text{M}$ ) demonstrating high potency ( $K_d = \sim 18 \mu\text{M}$ ).

**PHDM Inhibits PI(4,5)P<sub>2</sub> Phosphatases.** Next, we examined whether PHDM would be an effective inhibitor of PI(4,5)P<sub>2</sub>-metabolizing enzymes, since adding PHDM would lower the effective substrate (PI(4,5)P<sub>2</sub>) concentration. Thus, we tested the compound's potency on three different phosphoinositide phosphatases (SopB, OCRL, and SKIP) that preferentially hydrolyze PI(4,5)P<sub>2</sub>.<sup>21–25</sup>

As shown in Figures 3a–c, increasing concentrations of PHDM inhibit all tested phosphatases, implying that the compound is binding PI(4,5)P<sub>2</sub> potently, effectively competing with the enzymes for their substrate. Interestingly, compound PHDM seems to be more potent on OCRL and SKIP phosphatases, although all three enzymes display similar  $K_M$  toward PI(4,5)P<sub>2</sub>. However, this could be due to the wider substrate specificity of SopB, which also dephosphorylates the generated PI(4)P. To ensure that the observed reduction in phosphate release is not due to PHDM interacting with the enzyme, we employed 3-O-methylfluorescein phosphate (OMFP), an artificial substrate without any structural similarity to inositols. By employing this substrate any interaction of PHDM with the enzyme itself will become obvious, since the preferred target for PHDM, the substrate PI(4,5)P<sub>2</sub>, will be missing. As shown in Figure 3d, no significant decrease in enzyme activity was detected in the presence of 50  $\mu\text{M}$  PHDM as compared to the vehicle control. This proves that PHDM does not bind OMFP or the employed phosphatases SopB and SKIP. OCRL could not be tested in this manner, since it has no detectable OMFP activity. We therefore can conclude that the reduced phosphate release in the phosphatase assays is an effect of PHDM binding to the available PI(4,5)P<sub>2</sub> substrate and not due to interactions with the three tested enzymes.


**Specificity of PHDM toward the Head Group of Inositol Lipids.** Having confirmed that PHDM is capable of inhibiting PI(4,5)P<sub>2</sub> hydrolysis in phosphatase assays, we investigated the specificity of PHDM for different inositol phosphate head groups. First, we tested PHDM's ability to interact with the soluble head group of its target PI(4,5)P<sub>2</sub>, namely, I(1,4,5)P<sub>3</sub>. Previous studies have shown that the PLC-δ1 PH domain, the biological equivalent of PHDM, binds about 8-fold more strongly to the water-soluble I(1,4,5)P<sub>3</sub> than PI(4,5)P<sub>2</sub>.<sup>26</sup> To examine the binding affinity of PHDM to I(1,4,5)P<sub>3</sub> in comparison to PI(4,5)P<sub>2</sub>, we made use of the ability of phosphatase OCRL to hydrolyze I(1,4,5)P<sub>3</sub> as well as PI(4,5)P<sub>2</sub>.<sup>24</sup> Surprisingly, although I(1,4,5)P<sub>3</sub> resembles the head group of PI(4,5)P<sub>2</sub>, PHDM inhibits OCRL activity better when the lipid substrate is employed (see Figure 4a). This implies a stronger binding of PHDM to PI(4,5)P<sub>2</sub> than I(1,4,5)P<sub>3</sub>, which is in contrast to the PLC-δ1 PH domain, where I(1,4,5)P<sub>3</sub> is clearly favored over PI(4,5)P<sub>2</sub>. For comparison, PHDM was also tested for its ability to bind PI(3,4,5)P<sub>3</sub>, which is generated *in vivo* by the action of PI

Scheme 1



**Figure 2.** (a) Immobilized PI(4,5)P<sub>2</sub> was assayed in the dependence of PH domain concentration. (b) Competition ELISA for determination of dissociation constant of PHDM. Displacement curve is shown as a function of PHDM concentration. The  $K_d$  is determined to be  $17.6 \pm 10.1 \mu\text{M}$ . Data presented are the mean  $\pm$  the standard deviation of at least three independent experiments performed in triplicates ( $n = 3$ ).


3-kinase on PI(4,5)P<sub>2</sub>.<sup>1</sup> The balance of PI(4,5)P<sub>2</sub> and PI(3,4,5)P<sub>3</sub> is maintained by PTEN, which counteracts PI 3-kinase by dephosphorylating PI(3,4,5)P<sub>3</sub> at the 3'-position.<sup>27</sup> As shown in Figure 4a, PHDM was unable to influence PTEN's activity, indicating that PHDM does not bind PI(3,4,5)P<sub>3</sub> or PTEN. In order to investigate inositol phosphate isomers, all naturally occurring inositol-phospholipids were subjected to a SopB assay, since SopB is known to hydrolyze all of these lipids.<sup>21,28</sup> As shown in Figure 4b, the hydrolysis of PI(4,5)P<sub>2</sub> by SopB is reduced in the presence of 50 μM PHDM to about 20% of the solvent (DMSO) control. Strikingly, all other PI-lipids were only minimally affected by PHDM, demonstrating that this compound has a much lower binding affinity for these related inositol phosphate head groups. Finally, we tested the ability of PHDM to compete with lipid-binding proteins commonly used to detect phosphoinositides. Therefore, we modified a protein-lipid overlay assay, which is generally used to study binding affinities between lipids and PH domains.<sup>29</sup> Normally, lipids are adsorbed onto blotting membranes, which are then probed with labeled proteins revealing their corresponding specificity. As shown in Figure 4d, only the PI(4,5)P<sub>2</sub>-binding PLC-δ1 PH domain was effectively blocked at low micromolar concentrations, with a complete loss of PH domain binding above 10 μM PHDM. Binding of the Akt PH domain toward PI(3,4)P<sub>2</sub> was only significantly affected at PHDM concentration of 50 μM, whereas the other lipid binding domains seem to be unaffected by up to 50 μM PHDM.



**Figure 3.** (a–c) PI(4,5)P<sub>2</sub> hydrolyzing phosphatases SopB, OCRL, and SKIP were used in dose–response studies of compound PHDM. PI(4,5)P<sub>2</sub> was presented in octyl glucoside mixed micelles at a substrate concentration of 20 μM, which is around the KM value reported for these three enzymes (SKIP and OCRL: 23 μM,<sup>24</sup> SopB: 28 μM). Phosphatase activity was determined as described earlier.<sup>24</sup> The IC<sub>50</sub>'s were determined to be SopB,  $21.6 \pm 6.5 \mu\text{M}$ ; OCRL,  $7.0 \pm 0.6 \mu\text{M}$ ; SKIP,  $6.9 \pm 0.7 \mu\text{M}$ . (d) SopB and SKIP in phosphatase assay with artificial substrate 3-O-methylfluorescein phosphate (OMFP) with and without PHDM. PHDM was used at a concentration of 50 μM with 150 μM OMFP substrate. OCRL could not be tested in this manner, since it has no detectable OMFP activity.

**Compound PHDM Binds to PI(4,5)P<sub>2</sub> in NIH 3T3 Mouse Fibroblasts.** Collectively, the data presented above clearly demonstrate that PHDM is a potent and specific PI(4,5)P<sub>2</sub>-binding agent *in vitro*. In order to characterize the potency of PHDM in a cellular environment we first determined the cytotoxicity of PHDM on cells by using the MTT assay.<sup>30</sup> As shown in Figure 5a, PHDM has no cytotoxic effect when fibroblast cells were treated for 2 h at concentrations as indicated. Even after prolonged exposure of 16 h, cell viability was still maintained at ~80% of vehicle control.

Having confirmed that PHDM is not cytotoxic to fibroblast cells, we next investigated the compound's ability to compete



**Figure 4.** (a) Head group specificity of PHDM studied with OCRL/I(1,4,5)P<sub>3</sub>, PI(4,5)P<sub>2</sub>, and PTEN/PI(3,4,5)P<sub>3</sub>. The remaining phosphatase activities in the presence of 20 μM PHDM compared to control are shown. All 3 substrates were used at a concentration of 20 μM. (b) Head group specificity of PHDM toward all 7 inositol phospholipids in phosphatase assays with SopB. All tested inositol-phospholipids contain the same fatty acid composition (diC16, palmitoyl) to ensure comparison of PHDM specificity based only on the inositol head group. Lipids were presented in octyl glucoside mixed micelles at concentrations of 20 μM. PHDM was used at 50 μM, and the remaining SopB activities are presented as percentage of solvent control (no PHDM). The amounts of SopB employed were adjusted for each inositol-phospholipid to ensure similar turnover rates (for details see Supplementary Figure 2). (c) Protein–lipid overlay assay in the presence of PHDM. Inositol phospholipids were preincubated with increasing concentrations of PHDM followed by incubation with GST-tagged lipid-binding domains. Bound domains were visualized with anti-GST and horseradish peroxidase antibodies. Results shown are representative of 3 independent experiments.


with the PLC-δ1 PH domain for PI(4,5)P<sub>2</sub> in a cellular environment (fixed cells). NIH 3T3 cells were treated with increasing concentrations of PHDM, fixed, and subjected to PI(4,5)P<sub>2</sub> staining by employing the PLC-δ1 PH domain as a probe. As shown in Figure 5b, strong PI(4,5)P<sub>2</sub> staining can be observed in the vehicle (DMSO) control, with higher fluorescence intensity at the PI(4,5)P<sub>2</sub>-rich plasma membrane.<sup>31</sup> With increasing concentrations of PHDM, the PI(4,5)P<sub>2</sub> staining decreases (>5 μM PHDM) almost abolishing PI(4,5)P<sub>2</sub> staining at concentrations above 10 μM PHDM. This data demonstrate that PHDM is capable of crossing through cellular membranes (cell-permeable), reaching the inside of the cell where it then binds cellular PI(4,5)P<sub>2</sub>, effectively competing with the PH domain probe in a dose-dependent manner. In order to evaluate PHDM's ability to compete with the PLC-δ1 PH domain *in vivo*, we employed cells overexpressing GFP-labeled PLC-δ1 PH domains (see Figure 5c). Increasing concentrations of PHDM correlated with increasing translocation of the PH domain (green) from the plasma membrane to the cytosol, with a complete loss of membrane localization achieved at PHDM concentrations higher than 30 μM. This process appears to start after 10 min of exposure to PHDM, being nearly completed within 30 min (see Figure 5d). Taken together these data demonstrate the capability of PHDM to enter living cells, wherein this chemical PI(4,5)P<sub>2</sub> receptor displaces the natural PI(4,5)P<sub>2</sub>-binding proteins (i.e., PLC-δ1 PH domain), which in turn suggests that PHDM is binding its intended target in living cells.

**PHDM Inhibits PI(4,5)P<sub>2</sub>-Dependent Transferrin Endocytosis.** Having established that PHDM binds PI(4,5)P<sub>2</sub> *in vivo*, we investigated whether the PHDM-induced changes in free PI(4,5)P<sub>2</sub> levels would manifest in a changed cellular function.

PI(4,5)P<sub>2</sub> has been reported to regulate trafficking of numerous proteins to and from the plasma membrane that are required

for receptor endocytosis such as the internalization of the transferrin receptor.<sup>32</sup> Transferrin, an iron-binding glycoprotein, is transported into the cell by receptor-mediated endocytosis. However, depletion of plasma membrane PI(4,5)P<sub>2</sub> causes a severe inhibition of the uptake of transferrin in COS-7 cells.<sup>32</sup> We therefore investigated the effect of PHDM on transferrin receptor uptake in a similar fashion. As shown in Figure 6a (top panel), FITC-conjugated transferrin was internalized and distributed in punctuated structure dispersed throughout the cytoplasm (yellow color). However, in the presence of compound PHDM, the uptake of transferrin was drastically reduced (bottom panel; Figure 6a). These results demonstrate that PHDM inhibits the endocytosis of the transferrin receptor (Figure 6b), suggesting that it also blocks PI(4,5)P<sub>2</sub>-dependent signaling and membrane traffic.

**PHDM Decreases the Formation of Long Actin Stress Fibers in Fibroblast Cells.** Another cellular effector of PI(4,5)P<sub>2</sub> is the cytoskeleton, which is well known to interact directly with this lipid.<sup>4</sup> In particular, increases in cellular PI(4,5)P<sub>2</sub> levels stimulate the formation of stress fibers, whereas a loss of PI(4,5)P<sub>2</sub> leads to actin depolymerization.<sup>3,4</sup> There are three possible routes to deplete cellular PI(4,5)P<sub>2</sub>: first, PLC-mediated hydrolysis to I(1,4,5)P<sub>3</sub> and DAG; second, hydrolysis to PI(4)P by inositol-5-phosphatases; and finally, conversion to PI(3,4,5)P<sub>3</sub> by PI 3-kinases. The latter pathway can be easily employed to disturb PI(4,5)P<sub>2</sub> levels by activating PI 3-kinases via growth factor stimulation (e.g., insulin). As shown in Figure 6b, starved cells display long and densely packed stress fibers (visualized with phalloidin). In contrast, starved cells treated with 10 μM PHDM displayed shorter and less densely packed stress fibers. At the higher concentration of 50 μM actin stress fibers disappear nearly completely. These observations provide further evidence that PHDM is capable of binding to PI(4,5)P<sub>2</sub> *in vivo*, which will then in turn affect cellular function.




**Figure 5.** (a) Cytotoxicity of compound PHDM studied using MTT assay. NIH 3T3 cells were incubated with PHDM for 2 and 16 h at concentrations as indicated. The results are presented as the mean  $\pm$  the standard deviation of 4 independent experiments performed in triplicates ( $n = 4$ ). (b) Immunofluorescence of bound PLC- $\delta 1$  PH domain in the presence of PHDM. Starved NIH 3T3 fibroblast were treated with concentrations of PHDM as indicated, PFA-fixed, and incubated with GST-tagged PLC- $\delta 1$  PH domain, followed by incubation with Alexa 488-conjugated GST-specific antibody. Green channel, PI(4,5)P<sub>2</sub> staining; blue, DAPI counter stain. Scale bar: top panel, 100  $\mu\text{m}$ ; bottom panel, 10  $\mu\text{m}$ . Quantification of bound PH domain from fluorescence imaging using ImageJ are presented in the bar chart on the right side. Data for the quantification was obtained from 6 independent experiments ( $n = 6$ ) over a minimum of 180 cells. (c) NIH 3T3 cells were transiently transfected with an expression vector encoding GFP-tagged PLC- $\delta 1$  PH domain. Twenty-four hours after transfection, cells were treated with PHDM at indicated concentrations, PFA-fixed, and imaged. Scale bar: 10  $\mu\text{m}$ . Quantification of cells displaying predominantly cytosolic PLC- $\delta 1$  PH domain staining are presented in the bar chart on the bottom. Data for the quantification was obtained from 3 independent experiments ( $n = 3$ ) counting a total of 120 cells. (d) Live cells time-lapse study showing the release of GFP-tagged PLC- $\delta 1$  PH domain into the cytosol upon the addition of 40  $\mu\text{M}$  PHDM. Scale bar, 10  $\mu\text{m}$ . Results shown are representative of 8 independent experiments. (e) Control experiment to panel d where the solvent vehicle (DMSO) was added to the cells instead of PHDM. Scale bar: 10  $\mu\text{m}$ . Results shown are representative of 4 independent experiments.

**PHDM Decreases the Amount of Mitochondria.** We recently demonstrated that mitochondrial destiny is controlled by PI(4,5)P<sub>2</sub>.<sup>33</sup> In particular, targeting the PLC- $\delta 1$  PH domain toward the outer membrane of mitochondria caused a gradual fragmentation in the mitochondrial network and ultimately a loss of mitochondria, which could be partially rescued by PKC. This implies that a PI(4,5)P<sub>2</sub>-PLC-PKC-dependent process is controlling the survival of mitochondria, which can be overcome by masking the available PI(4,5)P<sub>2</sub> on the outer membrane of mitochondria. A chemical mimetic of the PLC- $\delta 1$  PH domain should therefore cause the loss of mitochondria, which indeed was observed when cells were treated with 50  $\mu\text{M}$  PHDM (Figure 6c).

Taking all these observations together, it is evident that PHDM is a potent chemical receptor mimicking the PLC- $\delta 1$  PH domain with respect to lipid binding. Our *in vitro* studies reveal that PHDM binds PI(4,5)P<sub>2</sub> selectively and with high affinity.<sup>34</sup> Until now, PI(4,5)P<sub>2</sub>-binding molecules, such as polylysine<sup>34</sup>

and neomycin<sup>35</sup> have been used to reduce endogenous PI(4,5)P<sub>2</sub> levels. However, both polylysine and neomycin lack specificity since both bind PI(4,5)P<sub>2</sub> and other polar lipids (e.g., PtdSer) via electrostatic interactions.<sup>13</sup> Langeland *et al.* demonstrated via binding experiments of column-immobilized polylysine and neomycin that both compounds bind to phosphatidylserine, phosphatidylinositol, and phosphatidylinositol monophosphate.<sup>36</sup> These two binding agents are therefore not ideal to study PI(4,5)P<sub>2</sub>-dependent functions. In contrast, PHDM displays high specificity for PI(4,5)P<sub>2</sub>, offering a valuable and unprecedented alternative to these tools. Much of its specificity and potency can most likely be attributed to the well-documented ability of boronic acid to form strong covalent bonds with *cis*-1,2-diols such as the *cis*-1,2-diol present in PI(4,5)P<sub>2</sub>.<sup>37</sup> This type of interaction has been exploited in the past to separate PI(3)P from PI(4)P in thin layer chromatography.<sup>38</sup> Since all 3-phosphorylated inositol lipids lack the *cis*-diol (2' and 3' hydroxyls of the



**Figure 6.** (a) Transferrin uptake in the presence of PHDM. NIH 3T3 cells were treated with 50  $\mu$ M PHDM or solvent control for 30 min followed by incubation with Alexa 488-conjugated human transferrin for 15 min. Right panel, DAPI (blue); middle panel, transferrin (yellow); left panel, merged images. Scale bar: 10  $\mu$ m. Quantification of the transferrin uptake assay was performed using ImageJ software (4 independent experiments over a minimum of 20 cells), which is presented in the bar chart on the right side. (b) PHDM induces depolymerization of stress fibers. Stress fiber formation was monitored with FITC-conjugated phalloidin staining. NIH 3T3 cells were serum starved for 16 h followed by treatment as indicated. Images shown are representative of 5 independent experiments ( $n = 5$ ). Scale bar: 10  $\mu$ m. (c) PHDM reduces the size of mitochondria in NIH 3T3 cells. Cells were treated with 50  $\mu$ M PHDM for 30 min followed by staining with MitoTracker probe for 15 min. Cells were fixed, counterstained with DAPI (blue)m and examined by fluorescence microscopy. Scale bar: 10  $\mu$ m. Statistical analysis of mitochondria fluorescence using particle count measurements in randomly chosen fluorescence positive cells (see bar chart on the right side) were performed using ImageJ over a minimum of 280 cells from 3 independent experiments ( $n = 3$ ). Scale bar: 10  $\mu$ m.

inositol; see Figure 1a), PHDM cannot bind any of these lipids with sufficient affinity. On the other hand, removing a phosphate on the inositol head group will weaken the interaction with the urea moiety of PHDM, which may explain why PHDM favors PI(4,5)P<sub>2</sub> over PI(4)P and PI(5)P, where the *cis*-diols are available for binding.

We have demonstrated that the high specificity of PHDM enables us to employ it as a research tool to study PI(4,5)P<sub>2</sub>-dependent processes in the cellular environment. Currently, altering cellular PI(4,5)P<sub>2</sub> levels requires the use of chemical dimerizers, biological lipid recognition domains or lipid metabolizing enzymes, which are prone to interference by protein–protein interactions. In addition, response times are subject to biological restraints, since the cell has to express sufficient amounts of protein prior to any observable effects.<sup>39–42</sup> In contrast, employing PHDM allows to disturb PI(4,5)P<sub>2</sub> levels in a dose-dependent and dynamic manner.

As a number of recent reviews pointed out, PI(4,5)P<sub>2</sub> might be a potential therapeutic target in numerous human diseases.<sup>6,43</sup> Since the level of PI(4,5)P<sub>2</sub> is tightly controlled by phosphoinositide kinases, phospholipases, and phosphatases, they have been the most obvious targets to manipulate the level of PI(4,5)P<sub>2</sub>.

Chemical biological research tools, such as PHDM, which are custom-designed to target a substrate (as opposed to a protein), could unlock great potential for modulation of biological functions and could well gain the same momentum in drug discovery programs in future years as protein-targeted molecules. One particular disease that could benefit in the future from PHDM is the Lowe syndrome caused by the loss of the OCRL PI(4,5)P<sub>2</sub> 5-phosphatase, which in turn results in elevated PI(4,5)P<sub>2</sub> levels.<sup>42</sup>

## METHODS

**Chemical Synthesis.** *Synthesis of Compound 2.* Mono-Boc-protected diamine 1 (0.92 g, 3.9 mmol, 1 equiv), 2-formylphenylboronic acid (0.58 g, 3.9 mmol, 1 equiv), and 3 Å molecular sieves were transferred to a round-bottom flask, which was sealed and purged with nitrogen. Anhydrous MeOH (18.4 mL) was added followed by triethylamine (5.43 mL, 39 mmol, 10 equiv), and the mixture was vigorously stirred at room temperature (RT) for 2 h, then at 40 °C for another 2 h. It was then allowed to cool to RT, and after addition of solid NaBH<sub>4</sub> (0.44 g, 11.7 mmol, 3 equiv) it was stirred at RT for 2 h. The mixture was

filtered through Celite, concentrated under vacuum, and treated with triethylorthoformate (1.95 mL, 11.7 mmol, 3 equiv) and a few drops of glacial acetic acid for 5–6 h at RT. The solvent was finally removed under vacuum, and the solid was washed with petroleum ether, water, and petroleum ether again and left to dry first on the filter and then on a high vacuum line. This process afforded the desired compound **2** in 89% yield (1.28 g, 3.47 mmol) as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 3.31 ppm) δ (ppm): 1.46 (9H, singlet), 3.86 (2H, singlet), 3.97 (2H, singlet), 4.25 (2H, singlet), 7.07 (1H, doublet, *J* = 6.5 Hz), 7.19 (2H, m), 7.34 (2H, doublet, *J* = 7.9 Hz), 7.42 (2H, doublet, *J* = 7.9 Hz), 7.48 (1H, doublet, *J* = 6.5 Hz). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 49.00 ppm) δ (ppm): 28.79, 44.73, 51.88, 54.13, 80.21, 124.25, 127.67, 128.34, 128.66, 129.79, 130.95, 131.62, 134.86, 141.42, 142.36, 158.54. LC-MS (ESI<sup>+</sup>): calculated (M + H) 371.21 amu; found 371.21 amu.

**Synthesis of Compound 3.** Compound **2** (0.24 g, 0.65 mmol, 1 equiv) was transferred to a round-bottom flask, which was sealed and purged with nitrogen. Anhydrous CH<sub>2</sub>Cl<sub>2</sub> (65 mL) was added, and the mixture was cooled to −78 °C before dropwise addition of TFA (3 mL, 40 mmol, 61.5 equiv). The mixture was vigorously stirred at −78 °C for 1 h, and then the temperature was allowed to slowly rise to RT over 5 h. The solvent was removed under vacuum to give compound **3** as a colorless oil, which was further dried on high vacuum for 24 h and used directly in the synthesis of **4** (see below). <sup>1</sup>H NMR indicated 100% boc deprotection, and <sup>13</sup>C and <sup>19</sup>F NMR suggested the presence of some remaining TFA, which on the basis of the obtained mass of 0.545 g was determined to be 5 equiv of TFA per molecule of **3**. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 3.31 ppm) δ (ppm): 4.17 (2H, singlet), 4.30 (4H, singlet), 7.43 (3H, broad singlet), 7.59 (4H, broad singlet), 7.80 (1H, broad singlet). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 49.00 ppm) δ (ppm): 43.73, 51.63, 52.81, 116.75 (TFA CF<sub>3</sub>, quartet), 129.88, 130.79, 131.64, 131.82, 131.99, 132.45, 133.27, 135.87, 136.70, 136.90, 167.09 (TFA carboxylate). LC-MS (ESI<sup>+</sup>): calculated (M + H) 271.16 amu; found 271.16 amu.

**Synthesis of Compound 4.** Compound **3**, as its TFA salt (0.44 g, 0.52 mmol, 2 equiv), was transferred to a round-bottom flask, which was sealed and purged with nitrogen. Anhydrous DMF (6 mL) was added, followed by addition of triethylamine (3.62 mL, 26 mmol, 100 equiv) at RT and stirring for 10 min. The excess triethylamine was used to neutralize residual TFA from the previous step. A solution of 4,4'-methylenebis(phenyl isocyanate) (0.065 g, 0.26 mmol, 1 equiv) in 1.5 mL of DMF was added dropwise, and the reaction was allowed to stir at RT for 48 h. The mixture was then concentrated under vacuum, and the product was precipitated out of solution as a white solid by addition of water. It was filtered and washed extensively with water and CH<sub>2</sub>Cl<sub>2</sub>. This process afforded 60% of compound **4** (0.123 g, 0.16 mmol). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 3.31 ppm) δ (ppm): 3.85 (2H, singlet), 3.86 (4H, singlet), 3.97 (4H, singlet), 4.40 (4H, singlet), 7.08 (6H, multiplet), 7.17 (4H, multiplet), 7.26 (4H, doublet, *J* = 8.6 Hz), 7.38 (4H, doublet, *J* = 8.2 Hz), 7.43 (4H, doublet, *J* = 8.2 Hz), 7.47 (2H, multiplet). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 49.00 ppm) δ (ppm): 41.47, 44.18, 51.85, 54.15, 120.61, 127.67, 128.30, 128.72, 129.82, 130.18, 131.03, 134.96, 137.25, 138.75, 141.61, 142.26, 145.74, 148.96, 158.36. LC-MS (ESI<sup>+</sup>): calculated (M + H) 791.39 amu; found 791.40 amu. IR (cm<sup>−1</sup>): 757, 813, 1235, 1309, 1361, 1414, 1514, 1544, 1600, 1660. Anal. Calcd for C<sub>45</sub>H<sub>48</sub>B<sub>2</sub>N<sub>6</sub>O<sub>6</sub>·1/2H<sub>2</sub>O: C, 67.6; H, 6.2; N, 10.5. Found: C, 67.7; H, 6.1; N, 9.9.

**Biological Methods. Protein Expression and Purification.** All lipid-binding domains, OCRL, SKIP, SopB, as well as PTEN, were expressed and purified as GST-fusion protein. Protein expression was induced in the *E. coli* strain DH5α for 24 h using 1 mM IPTG at 23 °C. After growth the cells were harvested and the pellet was stored at −20 °C. The harvested cells were resuspended in lysis buffer containing 50 mM Tris (pH 7.4), 1% Triton X-100, 10 mM benzamidine hydrochloride, 100 μg mL<sup>−1</sup> soybean trypsin inhibitor, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride, and 2 mM DTT. Lysozyme was

added to the cell suspension at a concentration of 2 mg mL<sup>−1</sup>, and the mixture was stirred for 1 h at 4 °C. Lysis was performed by sonication, followed by centrifugation at 18,000g for 1 h at 4 °C. The supernatant was loaded onto a glutathione sepharose column pre-equilibrated with 50 mM Tris (pH 7.4), 140 mM NaCl, and 2.7 mM KCl. After loading, the column was washed twice with 50 mM Tris (pH 7.4), 140 mM NaCl, 2.7 mM KCl, and 2 mM DTT. Another two washes were performed using the same buffer with 500 mM NaCl. The GST-tagged protein was eluted using 20 mM glutathione in 50 mM Tris (pH 7.4), 250 mM NaCl, 20% (v/v) glycerol, and 2 mM DTT. Protein integrity was confirmed by Western blotting using GST antibody. Protein concentration was determined using Bradford assay.

**Protein-Lipid Overlay Assay.** Inositol phospholipids were preincubated with increasing concentration of PHDM or solvent control for 20 min. A 50 pmol sample of inositol-phospholipid was spotted onto a nitrocellulose membrane followed by blocking with 0.25% (w/v) fatty-acid-free bovine serum albumin (BSA) in 50 mM TRIS buffer, pH 7.4. The membrane was washed 3 times with 50 mM TRIS pH 7.4 containing 150 nM sodium chloride and 0.1% (v/v) Tween 20 (TBST) for 5 min each. Membranes were then incubated with the corresponding lipid-binding domain in blocking buffer. The concentrations of lipid-binding domains were optimized to ensure a dose-dependent detection of bound lipid. The following concentrations of lipid-binding domains were used: 25 nM PLC-δ1 PH domain, 5 nM FYVE domain, 50 nM FAPP1 domain, 25 nM Akt PH domain, and 50 nM GRP1 PH domain. After 1 h of washing with TBST, bound PH domain was visualized using a GST antibody and horseradish-peroxidase-conjugated secondary antibody with 1 h of washing in TBST in between. The membrane was then probed using Western blotting detection reagent.

**Phosphatase Enzyme Assay with Inositol Phospholipid Substrates.** Inositol phospholipids were presented as mixed micelles with octyl glucoside. Therefore, lipids were sonicated with 1% (v/v) octyl glucoside in assay buffer (100 mM Tris, pH 7.4) for 10 min and added to the assay with a final concentration of 0.25% (v/v) octyl glucoside. Phosphatase activities were measured in 100 mM Tris, pH 7.4 and 4 mM MgCl<sub>2</sub> at 37 °C for 30 min. Reactions were terminated after 30 min by adding 2.25 vol of color reagent (5 mM malachite green oxalate, 17 mM ammonium heptamolybdate, 77 mM bismuth citrate, and 1.7 M HCl) to quantify the amount of phosphate release. The mixture was allowed to develop for 10 min at RT, and the absorbance was read at 625 nm. All enzyme assays were performed in a 96-well microtiter plate.

**Phosphatase Enzyme Assay with OMFP as Substrate.** 3-O-Methyl-fluorescein phosphate cyclohexylammonium salt (OMFP) was dissolved into anhydrous DMSO to a concentration of 20 mM and then further diluted with 1% (v/v) DMSO to the tested concentrations. Assays were performed in 100 mM TRIS (pH 7.4) containing 4 mM MgCl<sub>2</sub>. Reactions were initialized by adding OMFP to the enzyme–buffer mixture. The hydrolysis of OMFP to OMF was monitored by measuring the change of fluorescence units in a 96-well microtiter plate (excitation at 485 nm and emission at 525 nm) using a Varian fluorescence spectrophotometer.

**Cytotoxicity Assay.** NIH 3T3 cells were seeded into a 96-well plate at a concentration of ~8,000 cells per well and incubated at 37 °C for 16 h. Cells were treated with PHDM at concentrations between 5 and 50 μM for 2 or 16 h, respectively, at 37 °C (total volume of 100 μL). After 2 or 16 h, 20 μL of a 5 mg mL<sup>−1</sup> MTT solution was added to each well, and the mixture was incubated for a further 4 h at 37 °C. The media were removed carefully, 150 μL of 4 mM HCl in isopropyl alcohol was added to each well, and the mixture was incubated at RT for 15 min on an orbital shaker. The formation of formazan by viable cells was measured using a spectrophotometer at 590 nm.

**Detection of Cellular PI(4,5)P<sub>2</sub> via Immunofluorescence.** Detection of cellular PI(4,5)P<sub>2</sub> was performed according to the methods previously described with some modifications.<sup>44</sup> NIH 3T3 mouse fibroblasts were

grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% bovine calf serum in an atmosphere of 5% CO<sub>2</sub> at 37 °C. Cells were seeded onto glass coverslips in a 24-well plate and starved overnight in serum-free DMEM. Cells were incubated with PHDM or DMSO and fixed with 4% paraformaldehyde (PFA) for 15 min at RT. After 3 washes with 50 mM ammonium chloride in phosphate buffered saline (PBS), the plate was chilled on ice for 20 min, prior to permeabilization with 0.5% (w/v) saponin in PBS for 30 min. Coverslips were blocked with 3% fatty-acid-free bovine serum albumin (BSA), followed by 3 washes with NH<sub>4</sub>Cl/PBS. Then 100 nM GST-tagged PLC- $\delta$ 1 PH domain in blocking buffer was added to the cells and incubated for 1 h on ice. Cells were washed three times with NH<sub>4</sub>Cl/PBS, and an Alexa 488-conjugated GST-specific antibody was added and incubated for 1 h at RT. After 3 washes with PBS, cells were fixed with 2% PFA for 10 min at RT. Cells were washed 3 times with PBS and then treated with 300 nM 4',6-diamidino-2-phenylindole (DAPI) for nuclear counterstaining. Thoroughly washed coverslips were mounted onto glass slides using Mowiol supplemented with 0.6% (w/v) 1,4-diazabicyclo[2.2.2]octane. Fluorescence microscopy was performed using a Nikon TE 2000 fluorescence microscope. Filters used in the fluorescence experiments were band-pass for DAPI, FITC, and TRITC with excitation wavelength of (nm) 340–380, 465–495, and 540–580, respectively, and with emission wavelength of (nm) 435–485, 515–555, and 572–605, respectively. Images were digitally acquired with a CCD camera (Hamamatsu) for each fluorophore separately and processed using IPLab software v 3.65a and ImageJ.

**Transferrin Uptake Assay, Detection of Actin Stress Fibers, and Mitochondria Staining.** NIH 3T3 cells were grown on coverslips in 10% bovine calf serum DMEM for 24 h. Cells were incubated with compound PHDM at concentrations indicated or solvent control for 30 min in serum-free DMEM. Alexa 488-human transferrin conjugate was added in serum-free DMEM at a final concentration of 5  $\mu$ g mL<sup>-1</sup>, and any excess was washed away with acidic PBS and subsequently neutral PBS (after 15 min). For stress fibers detection cells were incubated with FITC-conjugated phalloidin for 1 h at RT. For mitochondria staining, cells were treated with MitoTracker Red 580 (Invitrogen) according to the manufacturer's protocol. Cells were PFA fixed, and nuclei were DAPI stained. The coverslips were mounted in MOWIOL mounting medium and subjected to fluorescence microscopy as described above.

**Fluorescence Time-Lapse Microscopy.** NIH 3T3 cells transfected with GFP-PLC- $\delta$ 1 PH domain were observed under a Nikon TE 2000 fluorescence microscope using a 100 $\times$  Fluor oil lens. Images were taken every 1 min after addition of PHDM or vehicle control.

## ■ ASSOCIATED CONTENT

**S Supporting Information.** This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: r.woscholski@imperial.ac.uk.

## ■ ACKNOWLEDGMENT

This work was supported by the Lowe Syndrome Trust (U.K.), the Leverhulme Trust (U.K.), and the Engineering and Physical Sciences Research Council (EPSRC, U.K.).

## ■ REFERENCES

- Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., and Waterfield, M. D. (2001) Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer. *Ann. Rev. Cell Dev. Biol.* 17, 615–675.
- Berridge, M. J., and Irvine, R. F. (1984) Inositol trisphosphate, a novel 2nd messenger in cellular signal transduction. *Nature* 312, 315–321.
- Sakisaka, T., Itoh, T., Miura, K., and Takenawa, T. (1997) Phosphatidylinositol 4,5-bisphosphate phosphatase regulates the rearrangement of actin filaments. *Mol. Cell. Biol.* 17, 3841–3849.
- Raucher, D., Stauffer, T., Chen, W., Shen, K., Guo, S., York, J. D., Sheetz, M. P., and Meyer, T. (2000) Phosphatidylinositol 4,5-bisphosphate functions as a second messenger that regulates cytoskeleton-plasma membrane adhesion. *Cell* 100, 221–228.
- Hilgemann, D. W., Feng, S., and Nasuhoglu, C. (2001) The complex and intriguing lives of PIP2 with ion channels and transporters. *Sci. STKE* 111, re19.
- McCrea, H. J., and De Camilli, P. (2009) Mutations in phosphoinositide metabolizing enzymes and human disease. *Physiology* 24, 8–16.
- Fruman, D. A., Meyers, R. E., and Cantley, L. C. (1998) Phosphoinositide kinases. *Annu. Rev. Biochem.* 67, 481–507.
- Blero, D., Payrastre, B., Schurmans, S., and Erneux, C. (2007) Phosphoinositide phosphatases in a network of signalling reactions. *Pflügers Arch.* 455, 31–44.
- McLaughlin, S., Wang, J., Gambhir, A., and Murray, D. (2002) PIP2 and proteins: interactions, organization, and information flow. *Annu. Rev. Biophys. Biomol. Struct.* 31, 151–175.
- Garcia, P., Gupta, R., Shah, S., Morris, A. J., Rudge, S. A., Scarlata, S., Petrova, V., McLaughlin, S., and Rebecchi, M. J. (1995) The pleckstrin homology domain of phospholipase C- $\delta$ 1 binds with high affinity to phosphatidylinositol 4,5-bisphosphate in bilayer membranes. *Biochemistry* 34, 16228–16234.
- Rohacs, T., and Nilius, B. (2007) Regulation of transient receptor potential (TRP) channels by phosphoinositides. *Pflügers Arch.* 455, 157–168.
- Gabev, E., Kasianowicz, J., Abbott, T., and McLaughlin, S. (1989) Binding of neomycin to phosphatidylinositol 4,5-bisphosphate (PIP2). *Biochim. Biophys. Acta, Biomembr.* 979, 105–112.
- Palmer, F. B. (1981) Chromatography of acidic phospholipids on immobilized neomycin. *J. Lipid Res.* 22, 1296–1300.
- Amendola, V., Fabbrizzi, L., and Mosca, L. (2010) Anion recognition by hydrogen bonding: urea-based receptors. *Chem. Soc. Rev.* 39, 3889–3915.
- Gale, P. A. (2011) Anion receptor chemistry. *Chem. Commun. (Cambridge, U. K.)* 47, 82–86.
- Kang, S. O., Begum, R. A., and Bowmnna-James, K. (2006) Amide-based ligands for anion coordination. *Angew. Chem., Int. Ed.* 45, 7882–7894.
- Katayev, E. A., Ustyryuk, Y. A., and Sessler, J. L. (2006) Receptors for tetrahedral oxyanions. *Coord. Chem. Rev.* 250, 3004–3037.
- Fossey, J. S., and James, T. D. (2009) Boronic acid based modular fluorescent saccharide sensors. *Rev. Fluoresc.* 4, 103–118.
- Nishiyabu, R., Kubo, Y., James, T. D., and Fossey, J. S. (2011) Boronic acid building blocks: tools for self assembly. *Chem. Commun. (Cambridge, U. K.)* 47, 1124–1150.
- Gillooly, D. J., Morrow, I. C., Lindsay, M., Gould, R., Bryant, N. J., Gaullier, J.-M., Parton, R. G., and Stenmark, H. (2000) Localization of phosphatidylinositol 3-phosphate in yeast and mammalian cells. *EMBO J.* 19, 4577–4588.
- Norris, F. A., Wilson, M. P., Wallis, T. S., Galyov, E. E., and Majerus, P. W. (1998) SopB, a protein required for virulence of *Salmonella dublin*, is an inositol phosphate phosphatase. *Proc. Natl. Acad. Sci. U.S.A.* 95, 14057–14059.
- Faucherre, A. I., Desbois, P., Nagano, F., Satre, V. r., Lunardi, J. l., Gacon, G. r., and Dorseuil, O. (2005) Lowe syndrome protein Ocr1 is translocated to membrane ruffles upon Rac GTPase activation: a new perspective on Lowe syndrome pathophysiology. *Hum. Mol. Genet.* 14, 1441–1448.
- Ijuin, T., Mochizuki, Y., Fukami, K., Funaki, M., Asano, T., and Takenawa, T. (2000) Identification and characterization of a novel inositol polyphosphate 5-phosphatase. *J. Biol. Chem.* 275, 10870–10875.

- (24) Schmid, A. C., Wise, H. M., Mitchell, C. A., Nussbaum, R., and Woscholski, R. (2004) Type II phosphoinositide 5-phosphatases have unique sensitivities towards fatty acid composition and head group phosphorylation. *FEBS Lett.* 576, 9–13.
- (25) Mallo, G. V., Espina, M., Smith, A. C., Terebiznik, M. R., Aleman, A., Finlay, B. B., Rameh, L. E., Grinstein, S., and Brumell, J. H. (2008) SopB promotes phosphatidylinositol 3-phosphate formation on *Salmonella* vacuoles by recruiting Rab5 and Vps34. *J. Cell Biol.* 182, 741–752.
- (26) Lemmon, M. A., and Ferguson, K. M. (2000) Signal-dependent membrane targeting by pleckstrin homology (PH) domains. *Biochem. J.* 350, 1–18.
- (27) Maehama, T., and Dixon, J. E. (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J. Biol. Chem.* 273, 13375–13378.
- (28) Steele-Mortimer, O., Knodler, L. A., Marcus, S. L., Scheid, M. P., Goh, B., Pfeifer, C. G., Duronio, V., and Finlay, B. B. (2000) Activation of Akt/Protein Kinase B in epithelial cells by the *Salmonella typhimurium* effector SigD. *J. Biol. Chem.* 275, 37718–37724.
- (29) Dowler, S., Kular, G., and Alessi, D. R. (2002) Protein lipid overlay assay. *Sci. STKE* 2002 16.
- (30) Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* 65, 55–63.
- (31) Watt, S. A., Kular, G., Fleming, I. N., Downes, C. P., and Lucocq, J. M. (2002) Subcellular localization of phosphatidylinositol 4,5-bisphosphate using the pleckstrin homology domain of phospholipase C delta1. *Biochem. J.* 363, 657–666.
- (32) Kim, S., Kim, H., Chang, B., Ahn, N., Hwang, S., Di Paolo, G., and Chang, S. (2006) Regulation of transferrin recycling kinetics by PtdIns[4,5]P2 availability. *FASEB J.* 20, 2399–2401.
- (33) Rosivatz, E., and Woscholski, R. (2011) Removal or masking of phosphatidylinositol(4,5)bisphosphate from the outer mitochondrial membrane causes mitochondrial fragmentation. *Cell. Signalling* 23, 478–486.
- (34) Zhang, H., Craciun, L. C., Mirshahi, T., Rohács, T., Lopes, C. M. B., Jin, T., and Logothetis, D. E. (2003) PIP2 activates KCNQ channels, and its hydrolysis underlies receptor-mediated inhibition of M currents. *Neuron* 37, 963–975.
- (35) Schacht, J. (1976) Inhibition by neomycin of polyphosphoinositide turnover in subcellular fractions of guinea-pig cerebral cortex *in vitro*. *J. Neurochem.* 27, 1119–1124.
- (36) Langeland, N., Moore, L. J., Holmsen, H., and Haarr, L. (1988) Interaction of polylysine with the cellular receptor for Herpes simplex virus type 1. *J. Gen. Virol.* 69, 1137–1145.
- (37) Bosch, L., Fyles, T., and James, T. D. (2004) Binary and ternary phenylboronic acid complexes with saccharides and Lewis bases. *Tetrahedron* 60, 11175–11190.
- (38) Walsh, J. P., Caldwell, K. K., and Majerus, P. W. (1991) Formation of phosphatidylinositol 3-phosphate by isomerization from phosphatidylinositol 4-phosphate. *Proc. Natl. Acad. Sci. U.S.A.* 88, 9184–9187.
- (39) Fili, N., Calleja, V., Woscholski, R., Parker, P., and Larijani, B. (2006) Compartmental signal modulation: Endosomal phosphatidylinositol 3-phosphate controls endosome morphology and selective cargo sorting. *Proc. Natl. Acad. Sci. U.S.A.* 103, 15473.
- (40) Varnai, P., Thyagarajan, B., Rohacs, T., and Balla, T. (2006) Rapidly inducible changes in phosphatidylinositol 4,5-bisphosphate levels influence multiple regulatory functions of the lipid in intact living cells. *J. Cell Biol.* 175, 377–382.
- (41) Zoncu, R., Perera, R. M., Sebastian, R., Nakatsu, F., Chen, H., Balla, T., Ayala, G., Toomre, D., and De Camilli, P. V. (2007) Loss of endocytic clathrin-coated pits upon acute depletion of phosphatidylinositol 4,5-bisphosphate. *Proc. Natl. Acad. Sci. U.S.A.* 104, 3793–3798.
- (42) Attree, O., Olivos, I. M., Okabe, I., Bailey, L. C., Nelson, D. L., Lewis, R. A., McLennan, R. R., and Nussbaum, R. L. (1992) The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. *Nature* 358, 239–242.
- (43) Im, E., and Kazlauskas, A. (2007) PtdIns-4,5-P2 as a potential therapeutic target for pathologic angiogenesis. *Exp. Opin. Ther. Targets* 11, 443–451.
- (44) Hammond, G. R. V., Schiavo, G., and Irvine, R. F. (2009) Immunocytochemical techniques reveal multiple, distinct cellular pools of PtdIns4P and PtdIns(4,5)P2. *Biochem. J.* 422, 23–35.